Otophylloside B Protects Against A[beta] Toxicity in Caenorhabditis elegans Models of Alzheimer's Disease

Abstract

Abstract

Alzheimer's disease (AD) is a major public health concern worldwide and the few drugs currently available only treat the symptoms. Hence, there is a strong need to find more effective anti-AD agents. Cynanchum otophyllum is a traditional Chinese medicine for treating epilepsy, and otophylloside B (Ot B), isolated from C. otophyllum, is the essential active component. Having previously identified anti-aging effects of Ot B, we evaluated Ot B for AD prevention in C. elegans models of AD and found that Ot B extended lifespan, increased heat stress-resistance, delayed body paralysis, and increased the chemotaxis response. Collectively, these results indicated that Ot B protects against A[beta] toxicity. Further mechanistic studies revealed that Ot B decreased A[beta] deposition by decreasing the expression of A[beta] at the mRNA level. Genetic analyses showed that Ot B mediated its effects by increasing the activity of heat shock transcription factor (HSF) by upregulating the expression of hsf-1 and its target genes, hsp-12.6, hsp-16.2 and hsp-70. Ot B also increased the expression of sod-3 by partially activating DAF-16, while SKN-1 was not essential in Ot B-mediated protection against A[beta] toxicity.

Graphical Abstract

[Figure not available: see fulltext.]

http://crossmark.crossref.org/dialog/?doi=10.1007/s13659-017-0122-1&domain=pdf

Web End = Nat. Prod. Bioprospect. (2017) 7:207214 DOI 10.1007/s13659-017-0122-1

http://crossmark.crossref.org/dialog/?doi=10.1007/s13659-017-0122-1&domain=pdf

Web End = ORIGINAL ARTICLE

Otophylloside B Protects Against Ab Toxicityin Caenorhabditis elegans Models of Alzheimers Disease

Jie Yang . Xiao-Bing Huang . Qin-Li Wan . Ai-Jun Ding . Zhong-Lin Yang . Ming-Hua Qiu . Hua-Ying Sun . Shu-Hua Qi . Huai-Rong Luo

Received: 22 December 2016 / Accepted: 1 February 2017 / Published online: 13 February 2017 The Author(s) 2017. This article is published with open access at Springerlink.com

Abstract Alzheimers disease (AD) is a major public health concern worldwide and the few drugs currently available only treat the symptoms. Hence, there is a strong need to nd more effective anti-AD agents. Cynanchum otophyllum is a traditional Chinese medicine for treating epilepsy, and otophylloside B (Ot B), isolated from C. otophyllum, is the essential active component. Having previously identied anti-aging effects of Ot B, we evaluated Ot B for AD prevention in C. elegans models of AD and found that Ot B extended lifespan, increased heat stress-resistance, delayed body paralysis, and increased the chemotaxis response. Collectively, these results indicated that Ot B protects against Ab toxicity. Further mechanistic studies revealed that Ot B decreased Ab deposition by decreasing the expression of Ab at the mRNA level. Genetic analyses showed that Ot B mediated its effects by increasing the activity of heat shock transcription factor (HSF) by upregulating the expression of hsf-1 and its target genes, hsp-12.6, hsp-16.2 and hsp-70. Ot B also increased the expression of sod-3 by partially activating DAF-16, while SKN-1 was not essential in Ot B-mediated protection against Ab toxicity.

Electronic supplementary material The online version of this article (doi:http://dx.doi.org/10.1007/s13659-017-0122-1

Web End =10.1007/s13659-017-0122-1 ) contains supplementary material, which is available to authorized users.

J. Yang Q.-L. Wan A.-J. Ding Z.-L. Yang M.-H. Qiu

H.-Y. Sun H.-R. Luo (&)

State Key Laboratory of Phytochemistry and Plant Resources in West China, Yunnan Key Laboratory of Natural Medicinal Chemistry, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, Yunnan, Chinae-mail: [email protected]

J. Yang Q.-L. Wan A.-J. Ding Z.-L. Yang

University of Chinese Academy of Sciences, Beijing 100049, China

J. YangThe Second Afliated Hospital of Kunming Medical University, Kunming 650101, Yunnan, China

X.-B. Huang H.-R. Luo

Key Laboratory for Aging and Regenerative Medicine, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, China

S.-H. QiGuangdong Key Laboratory of Marine Material Medical, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, China

123

208 J. Yang et al.

Graphical Abstract

Cynanchum otophyllum

CL2006

Decreased paralysis

CH3

HO

O

O

O O

O

O

CL4176

H

O H

H3C

H

O

CH3

Otophylloside B

Keywords Alzheimers disease Caenorhabditis elegans Otophylloside B b-Amyloid peptide HSF-1

1 Introduction

Alzheimers disease (AD) is a neurodegenerative disorder that is strongly related to aging. As the number one cause of senile dementia, it is now becoming a major public health concern around the world [1]. Paradoxically, there are only a few drugs approved for the AD treatment, and these drugs only treat the symptoms. To date, there are still no disease-modifying drugs available, and there is a strong need to nd more effective anti-AD drugs [2].

Although the etiology of AD remains unclear, a growing body of evidence implicates thatthe extracellular senile plaques that result from accumulation of b-amyloid (Ab) and intracellular tau protein tangles are key histopathological hallmarks of Alzheimers disease (AD), and that the neurotoxicity of Ab may play a central role in the pathogenesis of AD [3, 4].

Because of its short lifespan and amenability to genetic manipulation, Caenorhabditis elegans models that mimic human disease have been extensively used to study the disease mechanism and to screen potential drugs [5]. To study the neurotoxicity of Ab, multiple transgenic C. elegans strains expressing the human Ab142 peptides in either neurons or muscle cells have been constructed. For example, CL2006 has muscle-specic expression of Ab, leading to a progressive paralysis that starts in adulthood. CL4176 expresses Ab in muscle cells in temperature-sensitive manner [6], while CL2355 expresses Ab in the neurons, which may more accurately represent the amyloid induced toxicity seen in AD [7].

Qingyangshen (Cynanchum otophyllum) is a traditional Chinese medicine, whose root is used for the treatment of

epilepsy, rheumatic pain, kidney weakness and muscle injuries [8, 9]. Otophylloside B (Ot B) is a C-21 steroidal glycoside, the essential active ingredient of Qingyangshen. Ot B has been shown to inhibit the seizure-like locomotor activity of zebrash [10] and extends the lifespan of wild type worms [11]. Since nutraceuticals with pro-longevity properties often have the potential to delay the onset of AD [1216], we are wondering if Ot B could delay the Ab-induced pathological behavior in C. elegans.

Here, we used several AD transgenic C. elegans models to evaluate the potential of Ot B for the prevention of AD and to determine its molecular mechanism of action. Our results showed that Ot B extended the lifespan, improved the heat resistance, dramatically improved Ab-induced pathological behavior, for example, delayed the progression of body paralysis, and improved chemotaxis response. These results indicated that Ot B played a protective role against Ab toxicity. Further results showed that Ot B reduced the accumulation of Ab, probably by increasing the gene expression of several heat shock proteins (HSP).

2 Results and Discussion

2.1 Ot B Extends Lifespan and Increases Heat Stress Resistance in C. elegans with Muscle-Specic Expression of Ab

Treatment of CL2006 worms having muscle-specic expression of Ab with 50 lM of Ot B caused a signicant

123

Caenorhabditis elegans Models of Alzheimers Disease 209

increase in their lifespan compared with controls (p \ 0.005; Fig. 1b, Supplementary Table 1). We also measured the effect of Ot B on heat stress resistance and heat recovery in CL2006 worms. Ot B treatment suppressed the lethality of heat stress in heat resistance experiments and heat resistance recovery experiments (p \ 0.005; Fig. 1c, d, Supplementary Table 2). Together, these results indicated that Ot B slows aging and delays age-related degeneration in C. elegans with muscle-specic expression of Ab.

2.2 Ot B Delays the Progression of Body Paralysis, and Improves Chemotaxis Response

Paralysis is an apparent symptom of AD, and in C. elegans models of AD, it is a measurable phenotype that is considered as a result of Ab toxicity [17]. Our paralysis assay with CL2006 showed that Ot B delayed paralysis by21.4%, signicantly increasing the PT50 from 8.0 to10.1 days, which is comparable to 10.1 days in the

curcumin-treated positive control group (p \ 0.005;

Fig. 2a, b, c, Supplementary Table 3).

Our previous study showed that Ot B delayed aging and aging-related disorders [11], we were wondering if the delayed onset of paralysis was the result of an anti-aging effect, rather than a reduction in toxicity. To distinguish between these two hypotheses, we performed the paralysis assay in CL4176 worms, which express Ab in muscle cells in a temperature-sensitive manner, leading to paralysis in larval animals (Fig. 3a) [18, 19]. At 30 h post temperature up-shift, Ot B decreased the paralysis from 73.3% to51.1%, and 36 h later, 92.1% of the untreated worms became paralyzed, while only 79.4% of Ot B-treated and78.7% of curcumin-treated positive control worms were paralyzed (p \ 0.05; Fig. 3b, Supplementary Table 4).

Together, these results indicated that Ot B delayed paralysis in young adults, and that this benecial effect did not result from anti-aging.

The CL2355 strain expresses Ab in the neurons, which may more accurately represent toxicity of Ab seen in AD

A Control50M Ot B

B

1.0

O

O

O

FractionAlive

0.8

OH

CH3

OH

0.6

HO

O

O

O O

O

O

2+

H

O H

H

0.4

H3C

O

H

O

CH3

0.2

0.0

Otophylloside B

0 10 20 30 40 Days at 16

C

* *** ***

D

1.0

Control 50M Ot B

***

0.8

Control 50M Ot B

***

FractionAlive

FractionAlive

0.8

0.6

0.6

***

*

0.4

0.4

*

0.2

*

0.2

0.0

0.0

2 4 6 8 10 12 14

24h 48h

Hours at 35

Hours at 16

Fig. 1 Otophylloside (Ot B) extended lifespan and improved thermo-tolerance in a C. elegans model of AD. a Chemical structure of Ot B. b Survival curves of CL2006 animals treated with vehicle or 50 lM of Ot B. c Survival percentage of CL2006 animals in heat resistance experiments. Heat resistance experiments were carried out at 35 C and calculated by 2 h. d Survival percentage of CL2006 animals in heat resistance recovery experiment. The experiments were carried out at 35 C for 7 h, then transferred to 16 C and the number of dead

worms was measured after 24 and 48 h. All the assays were carried out in triplicate, and at least three independent trials were performed. The columns showed the mean value of three independent experiments with error bars representing SEM. *** represents p\0.001, * represents p \ 0.05, calculated using two-tailed t test. Statistical details and repetition of this experiment are summarized in Table S1,

S2 (Supplementary information)

123

210 J. Yang et al.

A

B C

D

PT50=8.0070.223

PT50=10.0890.156 PT50=10.0930.127

Control

50M Ot B

100M Cur

Percentage of Not Palarysis

1.00.80.60.40.20.0

Percentage of Palarysis

1.00.80.60.40.20.0

1.00.80.60.40.20.0

1.00.80.60.40.20.0

0 5 10 15 20

0 5 10 15 20

0 5 10 15 20 0 5 10 15 20

Days at 16 Days at 16 Days at 16

Days at 16

Fig. 2 Ot B delayed progression of body paralysis in CL2006 worms. a Survival curves of control, Ot B treated and Cur treated animals. b Percentage of paralysis of control animals. c Percentage of paralysis of Cur treated animals. d Percentage of paralysis of Ot B treated animals. Each bar represents the mean of four independent

experiments with error bars representing SEM. Each paralysis assay was conducted in triplicate and four trials were performed. Statistical details and repetition of this experiment are summarized in Table S3 (Supplementary information)

A

Control

100 M Cur

50 M Ot B

B *

*

* *

CL4176

C

Control

100 M Cur

50 M Ot B

CL4176

Percentage of Palarysis

Normal

Paralysis

1.0

0.4

Chemotaxis Index

n.s.

n.s.

0.8

*

0.3

**

0.6

0.2

n.s.

n.s.

0.4

0.2

0.1

0.0

24h 30h 36h

0.0 CL2122

CL2355

Fig. 3 Ot B delayed progression of body paralysis in CL4176 and increased the chemotaxis response in CL2355 worms. a Photomicro-graph showing CL4176 worms were paralyzed in larval animals. b Percentage of paralysis in CL4176 animals treated or non-treated with Ot B. 100 lM Curcumin was used as a positive control. Worms were grown at 16 C for 48 h, and then transferred to 25C. Paralysis experiments were carried out at 25 C and calculated the paralysis of

worms in 24, 30 and 36 h. c Chemotaxis index of CL2355 and its vector control, CL2122. Each bar represents the mean of three independent experiments with error bars representing SEM. ** represents p\0.01,* represents p\0.05, calculated using two-tailed t test. Statistical details and repetition of this experiment are summarized in Table S4, S5 (Supplementary information)

[20]. The chemotaxis response in C. elegans is mediated by interneurons to stimulate the motor neurons [21]. To determine if Ot B could protect against Ab toxicity to neurons, we performed the chemotaxis response assay in CL2355 worms, using the CL2122 strain as a vector control. The response is reported as a chemotaxis index. The results for the vector control (CL2122) showed no difference between Ot B treated, curcumin positive controls, and untreated worms. In CL2355 worms, Ot B signicantly improved the chemotaxis response (p \ 0.05;

Fig. 3c, Supplementary Table 5). These results indicated that Ot B protected against Ab toxicity to neurological functions.

2.3 Ot B Decreases Ab Deposition in C. elegans Model of AD by Downregulating the Expression of Ab

In CL2006 worms with muscle-specic Ab expression, Ab deposits are immunoreactive to anti-Ab antibodies, and then these deposits bind to thioavin S to produce deposits that can be viewed by confocal microscopy (Fig. 4a) [13]. To investigate if Ot B has a direct impact on the formation of Ab, we conducted a thioavin S staining experiment. The number of Ab deposits was scored in the worm head region. The results showed that the mean number of Ab deposits per nematode was signicantly reduced in CL2006 worms treated with Ot B, compared with untreated worms at both day 3

123

Caenorhabditis elegans Models of Alzheimers Disease 211

A B

C

A mRNA

*

*

Control 50 M Ot B

CL2006 Day 3 CL2006 Day 5

Control

50 M Ot B

A deposit numbers of worm

16 12

8 4 0

1.20.90.60.30.0

**

Day 3 Day 5

Relative Expression Fold

Control 50 M Ot B

Fig. 4 Ot B decreased Ab deposition by depressing expression of Ab. a Thioavin S staining of CL2006. Ot B treated CL2006 worms were stained with thioavin S on day 3 and day 5. White arrows indicate Ab deposits. b Number of Ab deposits in the worm head region.

50 lM Ot B signicantly reduced the number of Ab deposits in CL2006 both at day 3 and day 5. c The transcript level of Ab, measured by qRT-PCR. The transcript level of Ab was signicantly

downregulated by Ot B. The data was normalized to the expression of cdc-42. Each bar represents the mean value of three independent experiments with error bars representing SEM. ** represents p \

0.01,* represents p \ 0.05, calculated using two-tailed t test. Statistical details and repetition of this experiment are summarized in Table S6, S7 (Supplementary information)

A B C

Control

50 M Ot B

Control

50 M Ot B

Control

50 M Ot B

*

**

** **

*

Relative Expression Fold

2.01.51.00.50.0

Relative Expression Fold

2.01.51.00.50.0

Relative Expression Fold

2.01.51.00.50.0

n.s. n.s.

n.s. n.s.

n.s.

n.s. n.s.

daf-16 sod-3 dod-3 sip-1

skn-1 gst-4 gcs-1 nit-1

hsf-1hsp-12.6hsp-16.2hsp-70

Fig. 5 Gene expressions of transcription factors involved in Ab deposition in controls and Ot B-treated C. elegans. a qRT-PCR measurement of mRNA transcripts for daf-16 and its targeted genes dod-3, sip-1, sod-3. b qRT-PCR measurement of mRNA transcripts for skn-1 and its targeted genes gst-4, gcs-1 and nit-1. c qRT-PCR measurement of mRNA transcripts for hsf-1 and its major target genes hsp-12.6, hsp-16.2 and hsp-70. qRT-PCR was carried out using 2 DDC

T method and normalized to the expression of gene cdc-42. In

each experiment, control and experimental worms were conducted in parallel and repeated in three independent trials. Bars represent the mean value of three independent experiments with error bars representing SEM. ** represents p \ 0.01,* represents p \ 0.05, calculated using two-tailed t test. Statistical details and repetition of this experiment are summarized in Table S7 (Supplementary information)

and day 5 (p \ 0.05; Fig. 4b, Supplementary Table 6). We next performed qRT-PCR to examine the effect of Ot B on the expression of Ab. Ot B signicantly reduced Ab expression compared to untreated controls (p \ 0.05;

Fig. 4c, Supplementary Table 7). Collectively, these results showed the protection of Ot B against Ab toxicity may result from the ability to decrease Ab deposition by downregulating the expression of Ab at the mRNA level.

2.4 Ot B Alleviates Ab Toxicity Mainly Through the HSF-1 Transcription Factor

Previous studies in C. elegans models of AD showed that the transcription factors DAF-16, SKN-1, and HSF-1 were

involved in Ab deposition [22, 23]. We performed qRTPCR to test whether these regulators were involved in Ot B protection against Ab toxicity.

We found no difference in the expression of daf-16 and its target genes, dod-3 and sip-1 between non-treated and treated worms, while the expression of another target gene, sod-3 was signicantly upregulated (Fig. 5a, Supplementary Table 7). We speculated that DAF-16 may play a partial role in Ot B -mediated protection against Ab toxi-city. Meanwhile, there was no difference observed in the expression of skn-1 and its target genes, gst-4, gcs-1 and nit-1. This may indicate that SKN-1 is not essential in Ot B -mediated protection against Ab toxicity (Fig. 5b, Supplementary Table 7).

123

212 J. Yang et al.

HSF-1 was reported to alleviate Ab toxicity by disaggregating and degrading large Ab aggregates into peptides or amino acids [24]. Our results showed that the treatment of Ot B signicantly upregulated the expression of hsf-1 and its targeted genes hsp-12.6, hsp-16.2 and hsp-70 (p \ 0.05; Fig. 5c, Supplementary Table 7). Thus, heat shock protein (HSP) may be essential in Ot B-mediated protection against Ab toxicity.

3 Conclusion

Otophylloside B (Ot B), a C-21 steroidal glycoside, is an essential active ingredient of Qingyangshen (C. otophyllum). We recently demonstrated anti-aging effects of Ot B in C. elegans, and it has been reported that Ot B is neuroprotective in epilepsy [9, 11]. Our present study showed that Ot B extended lifespan in a C. elegans model of AD, increased heat stress-resistance, delayed the process of paralysis, and increased the chemotaxis response. Collectively, these results indicated that Ot B protected against Ab toxicity. The

Ab deposition assay and gene expression experiment showed this may result from the ability of Ot B to decrease Ab deposition by down-regulating the expression of Ab. The molecular mechanism study revealed that Ot B up-regulated the expression of several heat shock proteins (HSP), including hsf-1 and its target genes of hsp-12.6, hsp-16.2 and hsp-70. It may also increase the expression of sod-3 by partially activating the DAF-16, while SKN-1 was not essential in Ot B -mediated protection against Ab toxicity.

Taken together, these results indicate that Ot B has strong potential for development as a drug for AD prevention.

4 General Experimental Procedures

4.1 Chemicals and Strains

All strains were obtained from the Caenorhabditis Genetics Center (CGC) and maintained on NGM plates seeded with Escherichia coli OP50 at 16 C. The following strains were used in this study: CL4176 dvIs27[myo-3::Ab342 let

3UTR(pAF29); pRF4 (rol-6(su1006))], CL2006 dvIs2[p-CL12(unc-54::Ab142:) ? pRF4], CL2122 dvIs15 [(pPD30.38) unc-54(vector) ? (pCL26) mtl-2::GFP], and

CL2355 dvIs50[pCL45(snb-1::Ab142::3 UTR(long) ? mtl-2::GFP]I.

Ot B was dissolved in DMSO for storage and diluted in PBS to a concentration of 50 lM while in use. Then the dilutions were overlaid onto the NGM plates. The nal DMSO concentration was 0.1% after adding the drugs to the plates, and the negative control group had the same concentration of DMSO.

4.2 Lifespan Assay

The lifespan assays were carried out in CL2006 at 16 C. The strain was cultured for 23 generations before using for lifespan analysis. Lifespan assay were conducted as described previously [25]. In brief, for each assay, at least 40 synchronous L4 larvae or young adults were transferred to NGM plates containing inactivated OP50 (65 C for 30 min), treated with 40 lM of FUdR to inhibit the growth of progeny and scored every other day. Animals were transferred to fresh plates with or without drugs every 24 days. All assays were carried out in triplicate, and at least three independent trials were performed. Statistics were calculated by using an SPSS package. The mean lifespan values were calculated by a log-rank (Kaplan Meier) statistical test, with p \ 0.05 accepted as statistically signicant.

4.3 Heat Resistance Assay

For heat resistance assays, synchronous strains of CL2006 at L4 stage or young adults were transferred to plates with or without Ot B and incubated at 35 C. Dead animals were counted every 2 h. For heat resistance recovery assays, synchronous animals of CL2006 at L4 stage or young adults were transferred to plates with or without Ot B at 35 C for 7 h, then transferred to 16 C and dead animals were counted daily [26]. For each assay, at least 30 synchronous nematodes were studied, and three independent trials were performed. For statistical analysis, p values were calculated by a two-tailed t test, each consisting of control and experimental animals at the same time.

4.4 Worm Paralysis Assay

For the paralysis assay of the CL4176 strain,late L3 larvae were grown at 16 C for 48 h, then transferred to 25 C to induce the expression of Ab. Paralysis experiments were carried out at 25 C. Calculation of the numbers of paralyzed worms was done at 24, 30 and 36 h after the transfer to 25 C. For CL2006, paralysis experiments were carried out at 16 C. Worms were checked every day until all worms were paralyzed. Worms were scored as paralyzed if they exhibited halos of cleared bacteria around their heads or moved their head only or did not move at all when they were gently touched by platinum worm pick [19]. Curcumin (100 lM) was used as a positive control. For each assay, at least 30 synchronous L4 larvae or young adult nematodes were studied. All paralysis plots were done in triplicate and three independent trials were performed. Statistics were calculated by using an SPSS package. The mean paralysis was calculated by a log-rank

123

Caenorhabditis elegans Models of Alzheimers Disease 213

(KaplanMeier) statistical test, with p \ 0.05 accepted as statistically signicant.

4.5 Chemotaxis Assay

CL2355 and its vector control CL2122 were used in chemotaxis assays. Synchronized L1 larvae were treated with Ot B or the vehicle. Chemotaxis experiments were carried out at 23 C as described previously [27]. Briey, worms were placed to the center of the plate, and 1 lL0.1% benzaldehyde in 100% ethanol a with 1 lL of 1 M sodium azide was placed on one side of the plate, and 1 lL 100% ethanol along with 1 lL of 1 M sodium azide was placed on the opposite side. Curcumin (100 lM) was used as a positive control. The chemotaxis index was dened as follows: (number of worms at the attractant location number of worms at the control location)/total number of worms on the plate). A two-tailed t test was used to calculate p values.

4.6 Ab Deposition Assay

For the Ab deposition assay, CL2006 transgenic nematodes were xed in 4% paraformaldehyde/PBS, pH 7.4, for 24 h at 4 C, and then permeabilized in 5% fresh bmercaptoethanol, 1% Triton X-100, 125 mM Tris pH 7.4, in a 37 C incubator for 24 h. The worms were stained with 0.125% thioavin S (Sigma) in 50% ethanol for 2 min, destained for 2 min in 50% ethanol, washed with PBS and mounted on slides for microscopy. Fluorescence images were acquired using a 409 objective of a uorescence microscope. The Thioavin S-reactive deposits anterior of the pharyngeal bulb in individual animals were scored [22]. A two-tailed test was used to calculate p values.

4.7 Gene Expression Analysis by q-Real-Time PCR

Synchronized CL2006 L1 larvae were transferred to NGM plates cultured with or without Ot B and incubated at 16 C. Worms in the young adult stage were collected with

M9 buffer, then total RNA was extracted using RNAiso Plus (Takara) and converted to cDNA with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The cDNA of candidate genes were amplied and quantied in a Power SYBR Green PCR Master Mix (Applied Biosystems) on an ABI 7500 DNA analyzer (Applied Biosystems). Relative fold-changes for transcripts were calculated using 2 DDCT method, and normalized to cdc-42. The experiments were conducted in triplicate. The data were analyzed using a two-tailed t test, and a p value \0.05 was accepted as statistically signicant.

Acknowledgements We thank the Caenorhabditis Genetics Center (CGC) for providing all the Caenorhabditis elegans strains used in this work. We thank Professor Wei-Min Yang from Kunming Medical University for providing curcumin as a gift used in our work. This work was partially supported by the Natural Science Foundation of China (81671405 and 81370453), Natural Science Foundation of Yunnan province (2013FA045 and 2015FB172), and Open Funds of Guangdong Key Laboratory of Marine Materia Medica (LMM2016-1).

Compliance with Ethical Standards

Conict of interest The authors declare no conict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/

Web End =http:// http://creativecommons.org/licenses/by/4.0/

Web End =creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. J.C. Udeochu, J.M. Shea, S.A. Villeda, Clin. Exp. Neuroimmunol. 7, 114125 (2016)

2. J. Cummings, P.S. Aisen, B. DuBois, L. Frolich, C.R. Jack Jr., R.W. Jones, J.C. Morris, J. Raskin, S.A. Dowsett, P. Scheltens, Alzheimers Res. Ther. 8, 39 (2016)

3. S.T. Ferreira, W.L. Klein, Neurobiol. Learn. Mem. 96(4), 529543 (2011)

4. K.L. Viola, W.L. Klein, Acta Neuropathol. 129(2), 183206 (2015)

5. Q. Wang, F. Yang, W. Guo, J. Zhang, L. Xiao, H. Li, W. Jia, Z. Huang, Rejuvenation Res. 17(2), 205208 (2014)

6. V. Dostal, C.D. Link, J. Vis. Exp. 44, e2252e2252 (2010)7. A.L. Lublin, C.D. Link, Drug Discov. Today Technol. 10(1), e115e119 (2013)

8. J.K. Zhou, J. Lv, P. Zhou, J. Guizhou Norm. Coll. 26(12), 2326 (2010)

9. X. Long, F.C. Dai, X.H. Xiao, J. He, Z.D. He, J. Jilin Med. 19, 41354137 (2014)

10. J.L. Li, J. Zhou, Z.H. Chen, S.Y. Guo, C.Q. Li, W.M. Zhao, J. Nat. Prod. 78(7), 15481555 (2015)

11. J. Yang, Q.L. Wan, Q.Z. Mu, C.F. Wu, A.J. Ding, Z.L. Yang, M.H. Qiu, H.R. Luo, Nat. Prod. Bioprospect. 5(4), 177183 (2015)

12. A. Gutierrez-Zepeda, R. Santell, Z. Wu, M. Brown, Y. Wu, I. Khan, C.D. Link, B. Zhao, Y. Luo, BMC Neurosci. 6, 54 (2005)

13. M. Morita, K. Osoda, M. Yamazaki, F. Shirai, N. Matsuoka, H. Arakawa, S. Nishimura, Brain Res. 1295, 186191 (2009)

14. U. Arya, H. Dwivedi, J.R. Subramaniam, Exp. Gerontol. 44(67), 462466 (2009)

15. V. Dostal, C.M. Roberts, C.D. Link, Genetics 186(3), 857866 (2010)

16. H. Guo, M. Cao, S. Zou, B. Ye, Y. Dong, J. Gerontol. A Biol. Sci. Med. Sci. (2015). doi:http://dx.doi.org/10.1093/gerona/glv165

Web End =10.1093/gerona/glv165

17. C. Regitz, L.M. Dussling, U. Wenzel, Mol. Nutr. Food Res. 58(10), 19311940 (2014)

18. L. Xin, R. Yamujala, Y. Wang, H. Wang, W.H. Wu, M.A. Lawton, C. Long, R. Di, PLoS ONE 8(5), e63874 (2013)

19. A. Takahashi, T. Watanabe, T. Fujita, T. Hasegawa, M. Saito, M. Suganuma, Biosci. Biotechnol. Biochem. 78(7), 12061211 (2014)

123

214 J. Yang et al.

20. Y. Wu, Z. Wu, P. Butko, Y. Christen, M.P. Lambert, W.L. Klein, C.D. Link, Y. Luo, J. Neurosci. 26(50), 1310213113 (2006)

21. O. Hobert, J. Neurobiol. 54(1), 203223 (2003)22. A.L. Hsu, C.T. Murphy, C. Kenyon, Science 300(5622), 11421145 (2003)

23. X. Li, O. Matilainen, C. Jin, K.M. Glover-Cutter, C.I. Holmberg, T.K. Blackwell, PLoS Genet. 7(6), e1002119 (2011)

24. E. Cohen, J. Bieschke, R.M. Perciavalle, J.W. Kelly, A. Dillin, Science 313(5793), 16041610 (2006)

25. S.Q. Zheng, X.B. Huang, T.K. Xing, A.J. Ding, G.S. Wu, H.R. Luo, J. Gerontol. A Biol. Sci. Med. Sci. (2016). doi: http://dx.doi.org/10.1093/gerona/glw105

Web End =10.1093/ http://dx.doi.org/10.1093/gerona/glw105

Web End =gerona/glw105

26. T. Ogawa, Y. Kodera, D. Hirata, T.K. Blackwell, M. Mizunuma, Sci. Rep. 6, 21611 (2016)

27. X.G. Zhang, X. Wang, T.T. Zhou, X.F. Wu, Y. Peng, W.Q. Zhang, S. Li, J. Zhao, Front. Pharmacol. 7, 227 (2016)

123